ЗНАЧЕНИЕ АРТЕРИАЛЬНОЙ ЖЕСТКОСТИ И СУБКЛИНИЧЕСКОГО ВОСПАЛЕНИЯ В ОПРЕДЕЛЕНИИ ПРОГНОЗА ТРОМБОТИЧЕСКИХ ОСЛОЖНЕНИЙ ПРИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ
Аннотация
Приводятся результаты обследования и динамического наблюдения в течение года 111 пациентов с различными формами фибрилляции предсердий (ФП) и 29 пациентов без нарушения ритма. Показано отсутствие различий в уровне С-реактивного белка как маркера воспаления у пациентов с аритмией и без таковой. Выявлено повышение скорости распространения пульсовой волны (СРПВ) как характеристики артериальной жесткости при постоянной форме ФП относительно лиц с синусовым ритмом. Установлено прогностическое значение СРПВ
в аспекте риска развития тромботических осложнений.
Литература
A novel explanation for the cause of atrial fibrillation seen in atherosclerotic coronary artery disease: «downstream inflammation» hypothesis/T.S. Guvenc [et al.]//Med. Hypotheses. -2010. -Vol. 74, № 4. -P. 665-667.
Activation of inflammation and coagulation after infusion of C-reactive protein in humans/R.J. Bisoendial [et al.]//Circ. Res. -2005. -Vol. 96. -P. 714-716
Activation of the endogenous coagulation system in patients with atrial flutter: Relationship to echocardiographic markers of thromboembolic risk/G.S. Kamath [et al.]//Cardiol. J. -2010, Vol. 17, № 4, P. 390-396.
Association between arterial stiffness and platelet activation/F. Yamasaki [et al.]//J. Hum. Hypertens. -2005. -Vol. 19, № 7. -P. 527-533.
Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis/T. Liu [et al.]//J. Am. Coll. Cardiol. -2007. -Vol. 49, № 15. -P. 1642-1648.
Augmentation index and carotid intima-media thickness are differently related to age, C-reactive protein and oxidized low-density lipoprotein/P. Kampus [et al.]//J. Hypertens. -2007. -Vol. 25, № 4. -P. 819-825.
Boos, C.J. Endotoxemia, inflammation, and atrial fibrillation/C.J. Boos, G.Y. Lip, B. Jilma//Am. J. Cardiol. -2007. -Vol. 100, № 6. -P. 986-988.
Boos, C.J. Is atrial fibrillation an inflammatory disorder?/C.J. Boos, R.A. Anderson, G.Y. Lip//Eur. Heart J. -2006. -Vol. 27, № 2. -P. 136-149.
C-reactive protein and atrial fibrillation: «evidence for the presence of inflammation in the perpetuation of the arrhythmia»/M. Acevedo [et al.]//Int. J. Cardiol. -2006. -Vol. 108, № 3. -P. 326-331.
C-reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion/O. Wazni [et al.]//Heart. -2005. -Vol. 91, № 10. -P. 1303-1305.
C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation/P. Cirillo [et al.]//Cardiovasc. Res. -2005. -Vol. 68. -P. 47-55.
C-reactive protein makes human endothelium stiff and tight/K. Kusche-Vihrog [et al.]//Hypertension. -2010. -Mode of access: http://www.ncbi.nlm.nih.gov/pubmed/21149827. -Date of access: 1 0.01.201 1.
C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway in atherothrombosis/G. Yaron [et al.]//Br. J. Haematol. -2006. -Vol. 134. -P. 426-431.
C-reactive protein: interaction with the vascular endothelium and possible role in human atherosclerosis/C. Ferri [et al.]//Curr. Pharm. Des. -2007. -Vol. 13. -P. 1631-1645.
Cross-sectional relations of peripheral microvascular function, cardiovascular disease risk factors, and aortic stiffness: the Framingham Heart Study/G.F. Mitchell [et al.]//Circulation. -2005. -Vol. 112. -P. 3722-3728.
Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells/S.K. Venugopal [et al.]//Circulation. -2002. -Vol. 106. -P. 1439-1441.
Deshko, M. Arterial stiffness and endothelial dysfunction: unidirectional changes in paroxysmal atrial fibrillation/M. Deshko//5th International scientific conference of medical students and young doctors: Abstractbook, Bialystok, 20-21 May 2010/Medical University of Bialystok; ed. M. Jozwik -Bialystok: Koncept, 2010. -P. 55-56.
Devaraj, S. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects/S. Devaraj, T.W. Du Clos, I. Jialal//Arterioscler. Thromb. Vasc. Biol. -2005. -Vol. 25. -P. 1359-1363.
Devaraj, S. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis/S. Devaraj, D.Y. Xu, I. Jialal//Circulation. -2003. -Vol. 107. -P. 398404.
Ellinor P.T., Low A., Patton K.K., et al. C-Reactive protein in lone atrial fibrillation//Am J Cardiol. -2006. -Vol. 97, № 9. -P. 1346-1350.
Fay, W.P. Linking inflammation and thrombosis: Role of C-reactive protein/W.P. Fay//World J. Cardiol. -2010. -Vol. 2, № 11. -P. 365-369.
High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion/E. Watanabe [et al.]//Int. J. Cardiol. -2006. -Vol. 108, № 3. -P. 346-353.
Histological substrate of human atrial fibrillation/C. Chimenti [et al.]//Biomed. Pharmacother. -2010. -Vol. 64, № 3. -P. 177183.
Hypertension and paroxysmal atrial fibrillation: a novel predictive role of high sensitivity C-reactive protein in cardioversion and long-term recurrence/I. Rizos [et al.]//J. Hum. Hypertens. -2010. -Vol. 24, № 7. -P. 447-457.
Increased inflammatory cell infiltration in the atrial myocardium of patients with atrial fibrillation/M.C. Chen [et al.]//Am. J. Cardiol. -2008. -Vol. 102, № 7. -P. 861-865.
Increased thrombosis after arterial injury in human C-reactive proteintransgenic mice/H.D. Danenberg [et al.]//Circulation. -2003. -Vol. 108. -P. 512-515.
Inflammatory markers according to types of atrial fibrillation/O. Gedikli [et al.]//Int. J. Cardiol. -2007. -Vol. 120, № 2. -P. 1931 9 7.
Intracardiac and extracardiac markers of inflammation during atrial fibrillation/G.M. Marcus [et al.]//Heart Rhythm. -2010. -Vol. 7, № 2. -P. 149-154.
Issac, T.T. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data/T.T. Issac, H. Dokainish, N.M. Lakkis//J. Am. Coll. Cardiol. -2007. -Vol. 50, № 21. -P. 2021-2028.
Krishnamoorthy, S. Assessment of endothelial (dys)function in atrial fibrillation/S. Krishnamoorthy, S.H. Lim, G.Y.H. Lip//Ann. Med. -2009. -Vol. 41. -P. 576-590.
Mahmud, A. Arterial stiffness is related to systemic inflammation in essential hypertension/A. Mahmud, J. Feely//Hypertension. -2005. -Vol. 46, № 5. -P. 1118-1122.
Malik, A. Forearm vascular reactivity and arterial stiffness in asymptomatic adults from the community/A. Malik, V. Kondragunta, I.J. Kullo//Hypertension. -2008. -Vol. 51. -P. 1512-1518.
Nitric oxide regulates local arterial distensibility in vivo/I.B. Wilkinson [et al.]//Circulation. -2002. -Vol. 105. -P. 213-217
Ozaydin, M. Atrial fibrillation and inflammation/M. Ozaydin//World J. Cardiol. -2010. -Vol. 2, № 8. -P. 243-250.
Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function/F.L. Li-Saw-Hee [et al.]//Eur. Heart J. -2001. -Vol. 22. -P. 17411 747.
Recruitment of immune cells across atrial endocardium in human atrial fibrillation/T. Yamashita [et al.]//Circ. J. -2010. -Vol. 74, № 2. -P. 262-270.
Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community/R.B. Schnabel [et al.]//Circulation. -2010. -Vol. 121, № 2. -P. 200207.
Role of inflammation and oxidative stress in atrial fibrillation/J. Li [et al.]//Heart Rhythm. -2010. -Vol. 7, № 4. -P. 438-444.
Savelieva, I. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches/I. Savelieva, J. Camm//Europace. -2008. -Vol. 10, № 6. -P. 647-665.
Savelieva, I. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance/I. Savelieva, A. Kourliouros, J. Camm//Naunyn. Schmiedebergs. Arch. Pharmacol. -2010. -Vol. 381, № 3. -P. 1-13.
Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients/J.S. Kim [et al.]//Atherosclerosis. -2007. -Vol. 192, № 2. -P. 401-406.
Singh, U. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant/U. Singh, S. Devaraj, I. Jialal//Arterioscler. Thromb. Vasc. Biol. -2005. -Vol. 25. -P. 2216-2221.
Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation/B. Freestone [et al.]//Chest. -2007. -Vol. 132. -P. 1253-1258.
Source of inflammatory markers in patients with atrial fibrillation/I. Liuba [et al.]//Europace. -2008. -Vol. 10, № 7. -P. 848-853.
Vlachopoulos, C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness. A systematic review and meta-analysis/C. Vlachopoulos, K. Aznaouridis, C. Stefanadis//J. Am. Coll. Cardiol. -2010. -Vol. 55, № 13. -P. 1318-1327.
